** Cell therapy developer ProKidney's PROK.O shares dip ~10% in early morning trading
** BofA Global Research cuts stock rating to "underperform" from "neutral" and trims price objective to a Wall-Street low of $1 from $3
** Brokerage says the bearish rating is to reflect a more conservative peak sales outlook for REACT, the company's experimental cell therapy being tested as a treatment of diabetic chronic kidney disease (CKD)
** BofA sees REACT as a high-risk program, given limitations in its Phase 2 data, and remains cautious that PROK can significantly accelerate its expected Phase 3 timeline from the current target of Q3 2027
** Avg rating of six brokerages is "buy"; their median PT is $4.50, according to data compiled by LSEG
** Its stock has lost ~64% so far this year
(Reporting by Joel Jose in Bengaluru)
((joeljose@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。